Severe cardiac AL amyloidosis in an elderly patient with multiple SARS-CoV-2 reinfection: a case report

Introduction. The relationship between systemic amyloidosis and coronavirus disease 2019 (COVID-19) has not been sufficiently studied to date. This paper presents a case of the persistence of COVID-19 markers in an elderly patient with systemic amyloidosis.

Brief description. A 74-year-old patient with heart failure with preserved ejection fraction and type 2 diabetes was repeatedly hospitalized due to decompensated heart failure. Based on the data of protein electrophoresis with immunotyping, biopsy of subcutaneous fat and bone marrow, echocardiographic data, the patient was diagnosed with systemic AL amyloidosis with cardiac involvement. During hospitalizations in April, August and December 2020, positive polymerase chain reaction test for SARS-CoV-2 were obtained, while there were no clinical manifestations of infection for a long time and adequate antibody production.

Conclusion. A case report demonstrates multiple SARS-CoV-2 reinfection in a severe comorbid elderly patient, as an unfavorable prognostic factor.

1. Zhang Y, Coats AJS, Zheng Z, et al. Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:941-56. doi:10.1002/ejhf.1915.

2. Reznik EV, Nguyen TL, Stepanova EA, et al. Cardiac Amyloidosis: Internist and Cardiologist Insight. The Russian Archives of Internal Medicine. 2020;10(6):430-57. (In Russ.) doi:10.20514/2226-67042020-10-6-430-457.

3. Reznik EV, Nguyen TL, Ustyuzhanin DV, et al. "Red flags" for diagnosing infiltrative heart diseases. Russian Journal of Cardiology. 2023;28(1S):5259. (In Russ.). doi:10.15829/1560-4071-2023-5259.

4. Crees ZD, Stockerl-Goldstein K. COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury. Am J Med. 2022;135:S49-52. doi:10.1016/j.amjmed.2022.01.005.

5. Kastritis E, Wechalekar A, Schönland S, et al. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. Br J Haematol. 2020;190:346-57. doi:10.1111/bjh.16898.

6. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:1169-86. doi:10.1002/ejhf.1531.

7. Chakraborty C, Sharma AR, Sharma G, et al. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24:4016-26. doi:10.26355/eurrev_202004_20871.

8. Blokhin AA, Shishkin AN, Knyazeva AI. Cardiovascular complications due to coronavirus infection (COVID-19). Juvenis Scientia. 2022;8:6-14. (In Russ.) doi:10.32415/jscientia_2022_8_6_6-14.

9. Raisi-Estabragh Z, Cooper J, Salih A, et al. Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank. Heart. 2023;109:119-26. doi:10.1136/heartjnl-2022-321492.

10. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28:2398-405. doi:10.1038/s41591-022-02051-3.

11. Vorobieva PA. Recommendations for the outpatient management of covid-19 patients with the acute infection and post-covid syndrome. Health Care Standardization Problems. 2021;7-8:3-96. (In Russ.) doi:10.26347/1607-2502202107-08003-096.

12. Lewis E, Fine N, Miller RJH, et al. Amyloidosis and COVID-19: experience from an amyloid program in Canada. Ann Hematol. 2022;101:2307-15. doi:10.1007/s00277-022-04964-y.

13. Ho M, Zanwar S, Buadi FK, et al. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023;98:49-55. doi:10.1002/ajh.26762.

14. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stemcell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93. doi:10.7326/0003-4819-140-2-200401200-00008.

15. Sachchithanantham S, Offer M, Venner C, et al. Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica. 2015;100:146976. doi:10.3324/haematol.2015.128025.